Kliniken Essen Mitte (KEM)
Medical Director
Professor Andreas du Bois completed his medical degree in 1987 and completed his fellowship in Gynaecology and Obstetrics at the University of Freiburg in 1993. He then became consultant at St. Vincentius-Kliniken, Karlsruhe and was board certified and accredited for gynecological oncology. 1999 he was appointed Director of the Department of Gynecology and Gynecologic Oncology, Horst-Schmidt-Kliniken, Wiesbaden and Associate Professor at University of Mainz. 2011 he became Director of the Departmenf of Gynecology and Gynecologic Oncology at Kliniken Essen-Mitte (KEM), 2021 he was appointed Medical Director of KEM.
Prof. du Bois has lead several practice-changing international clinical trials. He founded the AGO Study Group in 1993 and co-founded the European Network of Gynaecological Oncological Trial groups (ENGOT) in 2007. He has been a member of GCIG executive board and European Society of Gynaecological Oncology (ESGO) council, was Chairman and Scientific Committee member of the GCIG and the ESMO-ESGO Ovarian Cancer Consensus Conferences. He authored > 500 publications with > 37,000 citations, and has an h index of 90. He has received multiple awards including the Arthur Walpole Award (2006), Ernst Wertheim Award (2006), MD Anderson Madrid Lifetime Award (2016), German Cancer Prize (2020) and the ESGO Lifetime Achievement Award (2021).
Moderator of 2 Sessions
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Chair(s)
Session Icon
Session Description
This session is dedicated to innovations in ovarian cancer biology, surgery and treatment. Speakers in this session will cover the role of “biology” in clinical outcomes and potential for surgical decision making, timing and new approaches. With the growing interest in intraoperative treatments, a critical appraisal of HIPEC will be performed. The second part will discuss current and emerging systemic therapies in the first-line setting and how the ongoing trials may change clinical practice. Next, several “hot topics” in ovarian cancer will be presented, including the mechanisms of resistance to PARP inhibitors, front-line maintenance therapy as part of standard-of-care (SOC) for at least 50% of women with ovarian cancer and the new and very promising developmental therapies. To close this session dedicated to ovarian cancer, a debate on the role of surgery for relapsed disease from the US and European perspectives will be debated.
Session Type
Poster Rounds & Sponsor Conversation Break
Date
10/01/2022
Session Time
02:05 PM - 02:35 PM
Room
Sponsor Conversation Area
Chair(s)
Session Icon
Session Description
Poster Rounds Groups O4, O5 & O6. For the full schedule, please click on the Poster Rounds green button on top of the interactive program or visit the IGCS 2022 Mobile App.
Presenter of 3 Presentations
Opening / Introduction
Session Name
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Session Icon
Presenter
Lecture Time
04:00 PM - 04:02 PM
• DEBATE 2: Pro
Session Name
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Session Icon
Presenter
Lecture Time
05:48 PM - 06:01 PM
DEBATE 1: SHARPENING THE SCALPEL WITH MOLECULAR BIOLOGY (28 min) – moderated by Andreas Du Bois
Session Name
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Session Icon
Presenter
Lecture Time
04:02 PM - 04:02 PM